Performance of Renal Allografts Perfused With Verapamil-Treated Perfusion Solution
Verapamil has been used in perfusion solution to improve kidney performance, but evidence was anecdotal, and no research has been reported on recipient outcomes. Our organization began a program to evaluate Verapamil's effect on pump performance, transplant rate, and recipient outcomes. One kidney in a pair was treated with Verapamil and one with standard perfusion. Donor inclusion criteria were age 18 or older and both kidneys were placed on the pump. The laterality of the treated kidney was changed every month to reduce bias. From January 1, 2020 to June 30, 2020, 88 kidneys were evaluated. Of those, 21 donors had both kidneys transplanted to different recipients, so for those 42 kidneys, recipient outcomes were evaluated. Small improvements in pump performance were observed in the Verapamil-treated kidneys and more were transplanted. No clinical differences were found in recipients between the Verapamil-treated and standard perfused kidneys. A larger cohort is needed to determine whether differences are significant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Progress in transplantation (Aliso Viejo, Calif.) - 31(2021), 4 vom: 02. Dez., Seite 373-380 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Boyer, Allison Jo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CJ0O37KU29 |
|---|
| Anmerkungen: |
Date Completed 28.01.2022 Date Revised 28.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/15269248211045999 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332520625 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332520625 | ||
| 003 | DE-627 | ||
| 005 | 20231225215735.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/15269248211045999 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332520625 | ||
| 035 | |a (NLM)34713753 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Boyer, Allison Jo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Performance of Renal Allografts Perfused With Verapamil-Treated Perfusion Solution |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2022 | ||
| 500 | |a Date Revised 28.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Verapamil has been used in perfusion solution to improve kidney performance, but evidence was anecdotal, and no research has been reported on recipient outcomes. Our organization began a program to evaluate Verapamil's effect on pump performance, transplant rate, and recipient outcomes. One kidney in a pair was treated with Verapamil and one with standard perfusion. Donor inclusion criteria were age 18 or older and both kidneys were placed on the pump. The laterality of the treated kidney was changed every month to reduce bias. From January 1, 2020 to June 30, 2020, 88 kidneys were evaluated. Of those, 21 donors had both kidneys transplanted to different recipients, so for those 42 kidneys, recipient outcomes were evaluated. Small improvements in pump performance were observed in the Verapamil-treated kidneys and more were transplanted. No clinical differences were found in recipients between the Verapamil-treated and standard perfused kidneys. A larger cohort is needed to determine whether differences are significant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a deceased organ donor | |
| 650 | 4 | |a health systems | |
| 650 | 4 | |a kidney graft | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a organ procurement | |
| 650 | 4 | |a organ transplantation | |
| 650 | 4 | |a renal transplantation | |
| 650 | 7 | |a Verapamil |2 NLM | |
| 650 | 7 | |a CJ0O37KU29 |2 NLM | |
| 700 | 1 | |a Ketcham, Rachael Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Hostetler, Clint Allen |e verfasserin |4 aut | |
| 700 | 1 | |a Orlowski, Jeffrey Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Squires, Ronald A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progress in transplantation (Aliso Viejo, Calif.) |d 2000 |g 31(2021), 4 vom: 02. Dez., Seite 373-380 |w (DE-627)NLM10856486X |x 1526-9248 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:4 |g day:02 |g month:12 |g pages:373-380 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/15269248211045999 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 4 |b 02 |c 12 |h 373-380 | ||